EUVIMEDObjevte EUVIMED
Crossref

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case‐Control Study

David K Carroll iD, Eric A Woodcock iD, Andrew King, Andrew R Isaacson iD, Brandtly Yakey iD, Bram A Dolcourt, Rachel Wein, Julia Cochrane, Aria Darling, Areej M Fares, Joshua Hoover, Yusuke Terasaki and 4 more

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-07 · 46 (7)

DOI: 10.1002/phar.70177 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2026-06-10. Written by David K Carroll and 15 co-authors. Institution: Detroit Medical Center, Detroit, Michigan, USA. Major MEDLINE topics: Buprenorphine, Extracorporeal Membrane Oxygenation, Analgesics, Opioid, Hypnotics and Sedatives. 48 references. Funded by: NIDA NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Introduction

Patients supported with extracorporeal membrane oxygenation (ECMO) frequently require prolonged, high‐intensity analgosedation because of neuromuscular blockade, pain related to procedures, and pharmacokinetic alterations. These exposures increase the risk of iatrogenic medication toxicity and withdrawal.

Objectives

We evaluated whether buprenorphine (BUP) use during ECMO reduced full agonist opioid exposure and improved sedation compared with matched comparators.

Methods

Using a retrospective matched case–control cohort design among ECMO patients in a cardiovascular intensive care unit, we contrasted 30 patients treated with BUP versus 30 comparator patients not treated with BUP (NO‐BUP) matched using an a priori deterministic hierarchy. Comparisons were anchored to two matched time points: (i) the day before BUP exposure and (ii) the day after attaining the full therapeutic BUP dose; NO‐BUP comparators were assessed on the analogous ECMO days. The primary outcome was the between‐group difference in change in daily intravenous morphine milligram equivalents (MME) across this time period.

Results

Each cohort included 27 venovenous and three venoarterial ECMO patients. Demographics and illness severity did not differ between groups. Groups significantly differed in MME change scores ( p < 0.001) with the BUP cohort decreasing significantly ( p < 0.001) from 184.1 (interquartile range [IQR] 70.2–367.2) to 0.0 (IQR 0.0–11.6) median MME whereas NO‐BUP comparators nonsignificantly decreased ( p = 0.517) from 230.8 (IQR 153.3–567.0) to 177.2 (IQR 85.3–663.1). Groups also differed ( p = 0.031) in time in target RASS range (−2 to 0); the BUP cohort significantly improved from 53.9% to 91.2% ( p < 0.001) whereas NO‐BUP comparators nominally improved from 37.8% to 46.1% ( p = 0.275). In the BUP cohort, there was no precipitated withdrawal, opioid‐induced constipation, or respiratory depression. Rates of tracheostomy, mortality, and extubation before decannulation did not differ significantly.

Conclusion

BUP initiation among ECMO patients was feasible and associated with a marked reduction in full agonist opioid exposure and improved light‐sedation target attainment. These findings are hypothesis‐generating given the retrospective design and potential residual confounding.

Subjects

MeSH terms (MEDLINE)

BuprenorphineExtracorporeal Membrane OxygenationAnalgesics, OpioidHypnotics and SedativesHumansRetrospective StudiesCase-Control StudiesFemaleMaleMiddle AgedAdultCohort Studies

Author keywords

buprenorphineextracorporeal membrane oxygenationintensive careopioidssedationwithdrawal

Substances

BuprenorphineAnalgesics, OpioidHypnotics and Sedatives

Authors and institutions

  • Detroit Medical Center, Detroit, Michigan, USA.
  • Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

ORCID profiles: David K Carroll, Eric A Woodcock, Andrew R Isaacson, Brandtly Yakey, Mark K Greenwald

Funding

  • NIDA NIH HHS

Cite

APA

Carroll, D. K., Woodcock, E. A., King, A., Isaacson, A. R., Yakey, B., Dolcourt, B. A., Wein, R., Cochrane, J., Darling, A., Fares, A. M., Hoover, J., Terasaki, Y., Coyle, B. E., Chittenden, E., Chacko, R., & Greenwald, M. K. (2026). Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case‐Control Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(7). https://doi.org/10.1002/phar.70177

Vancouver

Carroll DK, Woodcock EA, King A, Isaacson AR, Yakey B, Dolcourt BA, et al. Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case‐Control Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(7). doi:10.1002/phar.70177

BibTeX
@article{Carroll2026,
  author = {Carroll, David K and Woodcock, Eric A and King, Andrew and Isaacson, Andrew R and Yakey, Brandtly and Dolcourt, Bram A and Wein, Rachel and Cochrane, Julia and Darling, Aria and Fares, Areej M and Hoover, Joshua and Terasaki, Yusuke and Coyle, Brendan E and Chittenden, Edie and Chacko, Rachel and Greenwald, Mark K},
  title = {Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case‐Control Study},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1002/phar.70177}
}
Start for free →